ABCSG 65 / DEFINTIVE Overview
Diagnostic HER2DX-guided treatment For patIeNts wIth early-stage HER2-posiTIVE breast cancer
An international, multicenter, prospective, two-arm, randomized, open-label Phase III study designed to demonstrate that personalized treatment decisions in HER2-positive early-stage breast cancer using the HER2DX® diagnostic test improve quality of life without compromising outcomes and survival rates.
| Study Start: | (global): 11/2024, FPI 11/2024 (national): 07/2025 |
| Coordinating Investigator AT: | Rupert Bartsch, Vienna |
| Participants: | 315 (global), 70 (national) |
| Study Design: (Click to enlarge) |
 |
Share on